Parkinson’s disease (PD) is a progressive neurodegenerative condition that primarily affects dopamine‑producing neurons in the substantia nigra. As dopamine levels decrease, individuals develop hallmark motor symptoms such as tremor, bradykinesia, rigidity, and balance difficulties, along with a broad range of non‑motor symptoms – from sleep disruptions and mood changes to autonomic dysfunction.6 Importantly, Parkinson’s can present very differently depending on the underlying genetic mutations that are present, with GBA1, LRRK2, and PRKN being the most common. These variations influence factors such as age of onset, speed of progression, and the balance of motor vs non-motor symptoms. This has important implications for early detection and personalized therapy. This year, World Parkinson’s Day, calls for better access to information at diagnosis, Parkinson’s nurse specialists more accessible and flexible, responsive care as needs evolve. These steps are essential as early detection and disease‑modifying therapies become a reality in this space. For example, patients may present in primary care meaning increased awareness of early detection amongst GP/PCPs will help ensure treatments are prescribed to patients at the right time. To celebrate World Parkinson’s Day, HRW Synapse wanted to explore the recent developments towards early detection. The Shift towards Early Detection Parkinson’s can develop slowly, and it often takes decades before visible symptoms appear (depending on individual patients’ mutations). For most patients 60–80% of dopaminergic neurons may already be irreversibly damaged by the time classic motor symptoms emerge.2 This emphasises the urgent need for tools that detect PD earlier so disease‑modifying therapies are more likely to work. Recent advancements include: Biomarkers for Earlier and More Accurate Diagnosis -Recent studies have identified DOPA decarboxylase as a highly specific biomarker for Parkinson’s and Lewy body dementia. -Its concentration in cerebrospinal fluid is up to 2.5 times higher in affected individuals, and it clearly differentiates PD from Alzheimer’s disease, which is important because this is currently one of the biggest diagnostic challenges.5 -Meanwhile, α‑synuclein seed amplification assays (SAAs) detect trace amounts of misfolded α‑synuclein, which is the pathological hallmark of PD. SAAs are important for emerging biological definitions of PD and promise to shift diagnosis into the prodromal phase, which is well before symptoms are clinically visible.4 Blood-Based Detection: A Future Gamechanger -A breakthrough 2026 study revealed that subtle blood biomarkers linked to DNA repair and cellular stress appear as early as years or even decades before motor symptoms. -This short diagnostic window could transform PD screening and enable preventive intervention.2 The Role of DAT Imaging A dopamine active transporter (DAT) SPECT scans are not required for diagnosis, but they can help visualize dopamine transporter levels in the brain, strengthening diagnostic confidence when symptoms are atypical, early/mild, and overlapping with other movement disorders. DAT imaging is increasingly integrated with molecular biomarkers and genetics, forming multi‑modal diagnostic frameworks that improve accuracy and support early-stage clinical trials.4 Managing Parkinson’s: A Lifelong Journey Parkinson’s affects both motor and non‑motor domains, requiring support from a multidisciplinary team including neurologists, therapists, specialist nurses and mental health professionals. However, many patients remain without consistent access to information, coordinated care, or Parkinson’s specialist nurses. The 2026 “bridge the care gap” campaign addresses this issue, highlighting that improved pathways are essential as treatment options expand.1 Treatments: Current Options and What’s Coming Next Current Standard of Care: -Levodopa remains the most effective symptomatic therapy.6 -Device‑assisted and infusion therapies continue to evolve, including long‑term safety data for subcutaneous levodopa infusions (ABBV‑951).7 While these improve symptoms, they do not slow disease progression; this fuels intense industry interest in disease‑modifying therapies (which will rely on early detection). Pipeline and Industry Advances: Industry momentum is unprecedented, with: -130+ companies pursuing 150‑plus therapies across mechanistic classes.6 -Gene therapy (e.g., AB‑1005), anti‑inflammatory agents, α‑synuclein antibodies, LRRK2 inhibitors, and lysosomal‑targeted agents entering mid‑to‑late‑stage trials. Key developments focusing on some of the most common PD variations include: -Prasinezumab: New open‑label extension analyses from AD/PD 2026 suggest participants on prasinezumab may experience around 2 years less disease progression compared to predicted trajectories. This therapy is now advancing to a pivotal Phase III PARAISO trial.9 -BIIB122: A inhibitor in the Phase 2 LUMA trial, evaluating its potential to slow early‑stage PD. LRRK2 is one of the most common genetic mutations linked to PD, making this a highly relevant therapeutic strategy, with results expected in 2026.7 -Ambroxol: Originally a cough medicine, Ambroxol is now studied for its ability to boost lysosomal GCase activity and reduce α‑synuclein accumulation. Trials in early-stage PD – particularly among GBA1 mutation carriers (another common PD-associated mutation) are ongoing.8 All together, these innovations reflect a shift toward disease biology–targeted treatments, moving us closer to true disease modification. Addressing challenges across the Parkinson’s disease journey? Continue the conversation by filling in the Contact form below. References Parkinson’s Europe. (n.d.). World Parkinson’s Day. https://parkinsonseurope.org/campaigns/world-parkinsons-day/ [abnewswire.com] Chalmers University of Technology. (2026, January 29). A simple blood test could spot Parkinson’s years before symptoms. ScienceDaily. https://www.sciencedaily.com/releases/2026/01/260129080424.htm [neurosciencenews.com] IQVIA. (2025, June 4). What’s next in Parkinson’s disease? A look at the pipeline and clinical trials. https://www.iqvia.com/library/articles/parkinsons-disease-an-analysis-on-key-selected-pipeline-developments-and-clinical-trial-insights [neurosciencenews.com] Tolosa, E., Poewe, W., Noyce, A. J., Svenningsson, P., Mahlknecht, P., & Marti, M. J. (2026, February 13). Towards biomarker-based diagnosis of Parkinson disease. Nature Reviews Neurology. https://www.nature.com/articles/s41582-026-01185-z [ablesci.com] Neuroscience News. (2026, March 24). Precision biomarker for Parkinson’s and Lewy body dementia found. https://neurosciencenews.com/dopa-decarboxylase-parkinsons-lbd-30373/ [zenodo.org] DelveInsight. (2026, February 23). Parkinson’s disease clinical trial pipeline gains momentum: 130+ companies lead the charge in pioneering new treatments. ABNewswire. https://www.abnewswire.com/pressreleases/parkinsons-disease-clinical-trial-pipeline-gains-momentum-130-companies-lead-the-charge-in-pioneering-new-treatments-delveinsight_792182.html [parkinsonseurope.org] Meglio, M. (2026, January 2). Previewing Parkinson disease pipeline: Emerging trials to watch in 2026. NeurologyLive. https://www.neurologylive.com/view/previewing-parkinson-disease-pipeline-emerging-trials-to-watch-in-2026 [nature.com] American Parkinson Disease Association (APDA). (2025, May 14). New Parkinson’s disease treatments in the clinical trial pipeline. https://www.apdaparkinson.org/article/new-pd-treatments-clinical-trial-pipeline/ [trvst.world] Prothena Corporation plc. (2026, March 21). Prothena partners present data supporting next generation treatments for Parkinson’s and Alzheimer’s disease at AD/PD 2026. Business Wire. https://www.businesswire.com/news/home/20260321254343/en/Prothena-Partners-Present-Data-Supporting-Next-Generation-Treatments-for-Parkinsons-and-Alzheimers-Disease-at-ADPD-2026 [businesswire.com] Apply Now!